Bachrodt Amy
SEC CIK 2050422 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| MAZE | Maze Therapeutics, Inc. | SVP, Fin | 15.5K | — | $1.56M | 12 | 2025-12-29 | 2026-04-01 |
Most active insiders at MAZE, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Bernstein Harold | Pres, CMO, R, D | — | $9.02M |
| 2 | Coloma Jason V | CEO, Dir | — | $5.25M |
| 3 | Dandekar Atul | CSBO | — | $5.01M |
| 4 | Bachrodt Amy | SVP, Fin | — | $1.56M |
| 5 | Sohn Catherine A. | Dir | — | $1.15M |
| 6 | Courtney Phillips | GC, Corp. Sec | — | $104.8K |
| 7 | Third Rock Ventures GP V, LP | 10% | — | — |
| 8 | HOMCY CHARLES J | Dir | — | — |
Transactions 12
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-04-02 16:06 | 2026-04-01 | MAZE | Maze Therapeutics, Inc. | Bachrodt Amy | SVP, Fin | M - OptEx | $10.42 | +2,500 | 15.5K | +19% | +$26.1K |
| DMT | 2026-04-02 16:06 | 2026-04-01 | MAZE | Maze Therapeutics, Inc. | Bachrodt Amy | SVP, Fin | S - Sale+OE | $29.44 | -2,500 | 13.0K | -16% | -$73.6K |
| D | 2026-03-03 | 2026-03-02 | MAZE | Maze Therapeutics, Inc. | Bachrodt Amy | SVP, Fin | M - OptEx | $10.42 | +5,000 | 18.0K | +39% | +$52.1K |
| DM | 2026-03-03 | 2026-03-02 | MAZE | Maze Therapeutics, Inc. | Bachrodt Amy | SVP, Fin | S - Sale+OE | $45.20 | -5,000 | 13.0K | -28% | -$226.0K |
| DM | 2026-02-04 | 2026-02-02 | MAZE | Maze Therapeutics, Inc. | Bachrodt Amy | SVP, Fin | S - Sale+OE | $46.04 | -5,000 | 17.8K | -22% | -$230.2K |
| DM | 2026-02-04 | 2026-02-02 | MAZE | Maze Therapeutics, Inc. | Bachrodt Amy | SVP, Fin | M - OptEx | $10.42 | +5,000 | 17.8K | +39% | +$52.1K |
| DM | 2026-01-26 | 2026-01-22 | MAZE | Maze Therapeutics, Inc. | Bachrodt Amy | SVP, Fin | M - OptEx | $10.42 | +5,000 | 15.5K | +48% | +$52.1K |
| D | 2026-01-26 | 2026-01-22 | MAZE | Maze Therapeutics, Inc. | Bachrodt Amy | SVP, Fin | S - Sale+OE | $45.52 | -5,000 | 13.0K | -28% | -$227.6K |
| DM | 2026-01-06 | 2026-01-02 | MAZE | Maze Therapeutics, Inc. | Bachrodt Amy | SVP, Fin | M - OptEx | $10.42 | +5,000 | 13.2K | +61% | +$52.1K |
| DM | 2026-01-06 | 2026-01-02 | MAZE | Maze Therapeutics, Inc. | Bachrodt Amy | SVP, Fin | S - Sale+OE | $39.15 | -5,000 | 13.0K | -28% | -$195.8K |
| DM | 2025-12-31 | 2025-12-29+ | MAZE | Maze Therapeutics, Inc. | Bachrodt Amy | SVP, Fin | M - OptEx | $10.42 | +15.0K | 13.1K | New | +$156.3K |
| DM | 2025-12-31 | 2025-12-29+ | MAZE | Maze Therapeutics, Inc. | Bachrodt Amy | SVP, Fin | S - Sale+OE | $40.41 | -15.0K | 13.6K | -53% | -$606.2K |
Purchase Sale Sale after option exercise All abbreviations